Structure Therapeutics utilizes computational chemistry and physics-based modeling to translate GPCR structural insights into drug discovery. The company's lead product candidate, aleniglipron (GSBR-1290), is an oral small molecule GLP-1 receptor agonist currently in clinical trials for the treatment of obesity and type 2 diabetes. Additionally, the company is advancing an amylin receptor agonist portfolio, including ACCG-2671, for weight management and other metabolic conditions. Originally founded as ShouTi Inc., the company maintains research and development operations in both the United States and China. By focusing on oral small molecules, Structure Therapeutics seeks to overcome the manufacturing, distribution, and administration limitations associated with traditional peptide and biologic therapies.
